Finance

Company reports 4Q, year-end 2001 financial results

Published in AIDS Weekly, May 6th, 2002

Keryx Biopharmaceuticals, Inc., (KERX; KRX), a drug discovery company focused on developing innovative therapies through its proprietary technologies for the treatment of critical medical conditions including cancer and diabetes, released financial results for the fourth quarter and year ended December 31, 2001.

At December 31, 2001, the company reported cash, cash equivalents, interest receivable and investment securities of $37.9 million compared with cash, cash equivalents, interest receivable and investment securities of $48.9 million at December 31, 2000.

The net loss for the quarter ended December 31, 2001, was $2,661,000, or $0.13 per share,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2002-05-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry